Press Releases April 30, 2026 04:15 PM

CooperCompanies Announces Release Date for Second Quarter 2026

CooperCompanies schedules Q2 2026 earnings release and conference call on June 4, 2026

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
COO

CooperCompanies, a leading global medical device company, announced it will release its financial results for the second quarter of 2026 on June 4, 2026. The company will host a conference call to discuss results and corporate updates following the release.

CooperCompanies Announces Release Date for Second Quarter 2026
COO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • CooperCompanies operates through two main business units: CooperVision (contact lenses) and CooperSurgical (fertility and women's healthcare).
  • The company serves global markets, selling products in over 130 countries and impacting more than 50 million lives annually.
  • An investor conference call is scheduled immediately after the earnings release to discuss financial results and company developments.

SAN RAMON, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- CooperCompanies (Nasdaq: COO), a leading global medical device company, announced today it will report second quarter 2026 financial results on Thursday, June 4, 2026, at 4:15 PM ET. Following the release, the Company will host a conference call at 5:00 PM ET to discuss the results and current corporate developments.

The dial-in number for the call is 800-715-9871 and the conference ID is 6529381. A simultaneous audio webcast and subsequent replay can be accessed at www.investor.coopercos.com

About CooperCompanies

CooperCompanies (Nasdaq: COO) is a leading global medical device company focused on helping people experience life’s beautiful moments through its two business units, CooperVision and CooperSurgical. CooperVision is a trusted leader in the contact lens industry, helping to improve the way people see each day. CooperSurgical is a leading fertility and women’s healthcare company dedicated to putting time on the side of women, babies, and families at the healthcare moments that matter most. Headquartered in San Ramon, CA, CooperCompanies has a workforce of more than 15,000, sells products in over 130 countries, and positively impacts over fifty million lives each year. For more information, please visit www.coopercos.com

Contact:
Kim Duncan
Vice President, Investor Relations and Risk Management
925-460-3663
ir@cooperco.com


Risks

  • Market reaction may be influenced by the actual financial results, which remain unknown at the time of this announcement.
  • Economic and healthcare sector uncertainties could impact CooperCompanies' business performance.
  • Global supply chain or regulatory changes could affect product availability or business operations.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026